SCM
AMED

Silvant Capital Management’s Amedisys AMED Stock Holding History

Silvant Capital Management’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-866
Closed -$212K – 330
2021
Q2 		$212K Hold
866
– – 0.03% 180
2021
Q1 		$229K Hold
866
– – 0.04% 177
2020
Q4 		$254K Hold
866
– – 0.04% 171
2020
Q3 		$205K Hold
866
– – 0.04% 172
2020
Q2 		$172K Hold
866
– – 0.03% 180
2020
Q1 		$159K Buy
+866
New +$154K 0.03% 168

Other funds holding AMED

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Silvant Capital Management's AMED Position: Q3 2021 in Review

Silvant Capital Management sold out of Amedisys (AMED) in Q3 2021, closing a stake of 866 shares — an estimated $212K sold.

Silvant Capital Management first reported a position in AMED in Q1 2020 and held it in 6 quarters. The position peaked at $254K in Q4 2020. 351 funds tracked by Wall St. Rank hold AMED as of Q3 2021.

  • Silvant Capital Management reported no remaining Amedisys position as of Q3 2021 after selling out during the quarter.
  • Silvant Capital Management sold 866 Amedisys shares in Q3 2021, an estimated $212K.
  • Silvant Capital Management first reported a position in Amedisys in Q1 2020 and held it in 6 quarters.
  • Silvant Capital Management's Amedisys position peaked at $254K in Q4 2020.
  • 351 funds tracked by Wall St. Rank held Amedisys as of Q3 2021.

Based on Silvant Capital Management's 13F filing for Q3 2021, filed 8 Nov 2021.